WASHINGTON, Nov. 17, 2008 – Finkelstein Thompson LLP announces that it is investigating potential shareholder claims involving AtriCure, Inc. (“Atricure” or the “Company”) (NasdaqGM: ATRC).

On November 3, 2008, AtriCure shares plunged 39% after the Company revealed that its marketing practices are being investigated by the Department of Justice (“DOJ”). According to an AtriCure press release, the DOJ wrote a letter to the Company stating that it was investigating AtriCure’s alleged marketing of the off-label use of the Company’s surgical tissue-ablation system to treat atrial fibrillation. The letter also stated that the DOJ is investigating whether AtriCure directed hospitals to bill for surgical-ablation procedures using incorrect billing codes. On this news, the Company’s stock fell nearly 40% to close at $3.89 per share on unusually high trading volume.

Finkelstein Thompson LLP has spent almost three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions.

Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.If you are an AtriCure shareholder and wish to discuss your rights and interests as an investor, please contact our Washington, D.C. office toll-free at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it